中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 2
Feb.  2023
Turn off MathJax
Article Contents

Value of blood ammonia and cholinesterase in the early diagnosis of liver cirrhosis with minimal hepatic encephalopathy

DOI: 10.3969/j.issn.1001-5256.2023.02.013
Research funding:

Natural Science Foundation of Ningxia (2022AAC03487);

Science and Technology Key Research Program of Ningxia (2019BEG03037);

School-level Scientific Research Project of Ningxia Medical University (XM2021069)

More Information
  • Corresponding author: DING Xiangchun, 13619511768@163.com (ORICD: 0000-0003-0283-9419); WANG Xiaodong, xdw80@yeah.net (ORICD: 0000-0003-3535-8208)
  • Received Date: 2022-07-13
  • Accepted Date: 2022-08-14
  • Published Date: 2023-02-20
  •   Objective  To investigate the value of serum markers in the early diagnosis of liver cirrhosis with minimal hepatic encephalopathy (MHE).  Methods  A prospective analysis was performed for 81 patients who were hospitalized and treated in General Hospital of Ningxia Medical University from April 2020 to February 2022, and all these patients were diagnosed with hepatitis B cirrhosis based on clinical manifestation, laboratory examination, and radiological examination or liver biopsy. According to digital connection test A (NCT-A) and digital symbol test (DST), these patients were divided into simple cirrhosis group with 45 patients and MHE group with 36 patients. Related indices were measured, including liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and total bilirubin (TBil)], albumin, blood ammonia, cholinesterase, and prothrombin time. The independent samples t-test was used for comparison of normally distributed continuous data between two groups; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups; the chi-square test was used for comparison of categorical data between groups. The logistic regression analysis and the area under the ROC curve (AUC) were used to investigate the predictive factors for MHE.  Results  Compared with the simple cirrhosis group, the MHE group had a significant increase in NCT-A score (Z=-7.110, P < 0.001) and a significant reduction in DST score (t=12.223, P < 0.001). The univariate analysis showed that there were significant changes in AST, albumin, prothrombin time, cholinesterase, and blood ammonia in the patients with MHE (Z=-2.319, -2.643, -1.982, -6.594, and -5.331, all P < 0.05), while the multivariate analysis showed that only cholinesterase and blood ammonia were significant predictive factors (all P < 0.05) and were correlated with Child-Pugh score (all P < 0.05). Cholinesterase, blood ammonia, and their combination had an AUC of 0.925, 0.845, and 0.941, respectively, in the diagnosis of MHE, with an optimal cut-off value of 2966, 60, and 0.513, respectively.  Conclusion  Blood ammonia, cholinesterase, and their combined measurement have a potential clinical value in the early diagnosis of liver cirrhosis with MHE.

     

  • loading
  • [1]
    REGA D, AIKO M, PEÑARANDA N, et al. Patients with minimal hepatic encephalopathy show altered thermal sensitivity and autonomic function[J]. J Clin Med, 2021, 10(2): 239. DOI: 10.3390/jcm10020239.
    [2]
    MONTAGNESE S, BAJAJ JS. Impact of hepatic encephalopathy in cirrhosis on quality-of-life issues[J]. Drugs, 2019, 79(Suppl 1): 11-16. DOI: 10.1007/s40265-018-1019-y.
    [3]
    YANG X, LIU W, DANG P, et al. Decreased brain noradrenaline in minimal hepatic encephalopathy is associated with cognitive impairment in rats[J]. Brain Res, 2022, 1793: 148041. DOI: 10.1016/j.brainres.2022.148041.
    [4]
    CÓRDOBA J, MÍNGUEZ B. Hepatic encephalopathy[J]. Semin Liver Dis, 2008, 28(1): 70-80. DOI: 10.1055/s-2008-1040322.
    [5]
    GU TM, ZHANG Y, JJIANG YP, et al. Efficacy of acarbose-linked ornithine aspartate in hepatic encephalopathy in cirrhotic patients[J]. Chin J Mod Appl Pharm, 2018, 35(10): 1538-1542. DOI: 10.13748/j.cnki.issn1007-7693.2018.10.023.

    顾体梅, 张勇, 江永平, 等. 阿卡波糖联合门冬氨酸鸟氨酸对肝硬化患者肝性脑病的疗效评估[J]. 中国现代应用药学, 2018, 35(10): 1538-1542. DOI: 10.13748/j.cnki.issn1007-7693.2018.10.023.
    [6]
    FICHET J, MERCIER E, GENÉE O, et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy[J]. J Crit Care, 2009, 24(3): 364-370. DOI: 10.1016/j.jcrc.2009.01.008.
    [7]
    PESSIDJO DJOMATCHO L, KOWO MP, NDAM AN, et al. Normalisation of the psychometric encephalopathy score within the Cameroonian population[J]. BMC Gastroenterol, 2021, 21(1): 287. DOI: 10.1186/s12876-021-01858-7.
    [8]
    HA ZY, MATHEW S, YEONG KY. Butyrylcholinesterase: a multifaceted pharmacological target and tool[J]. Curr Protein Pept Sci, 2020, 21(1): 99-109. DOI: 10.2174/1389203720666191107094949.
    [9]
    TURECKY L, KUPCOVA V, DURFINOVA M, et al. Serum butyrylcholinesterase activities in patients with non-alcoholic fatty liver disease. Comparison with liver proteosynthetic function and liver fibrosis[J]. Bratisl Lek Listy, 2021, 122(10): 689-694. DOI: 10.4149/BLL_2021_110.
    [10]
    PAREKH PJ, BALART LA. Ammonia and its role in the pathogenesis of hepatic encephalopathy[J]. Clin Liver Dis, 2015, 19(3): 529-537. DOI: 10.1016/j.cld.2015.05.002.
    [11]
    ZIMMERMANN M, REICHERT AS. Rapid metabolic and bioenergetic adaptations of astrocytes under hyperammonemia-a novel perspective on hepatic encephalopathy[J]. Biol Chem, 2021, 402(9): 1103-1113. DOI: 10.1515/hsz-2021-0172.
    [12]
    PALOMERO-GALLAGHER N, ZILLES K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review[J]. Arch Biochem Biophys, 2013, 536(2): 109-121. DOI: 10.1016/j.abb.2013.02.010.
    [13]
    FIATI KENSTON SS, SONG X, LI Z, et al. Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy[J]. J Gastroenterol Hepatol, 2019, 34(1): 31-39. DOI: 10.1111/jgh.14408.
    [14]
    XU XY, DING HG, LI WG, et al. Chinese guidelines on the management of liver cirrhosis[J]. Clin Hepatal, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [15]
    Chinese Society of Gastroenterology, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Consensus on diagnosis and treatment of hepatic encephalopathy in China (Chongqing, 2013)[J/CD]. Chin J Front Med Sci (Electronic Version), 2014, 6(2): 81-93.

    中华医学会消化病学分会, 中华医学会肝病学分会. 中国肝性脑病诊治共识意见(2013年, 重庆)[J/CD]. 中国医学前沿杂志(电子版), 2014, 6(2): 81-93.
    [16]
    WANG JY, ZHANG NP, CHI BR, et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China[J]. World J Gastroenterol, 2013, 19(30): 4984-4991. DOI: 10.3748/wjg.v19.i30.4984.
    [17]
    HANSEN M, KJÆRGAARD K, ERIKSEN LL, et al. Psychometric methods for diagnosing and monitoring minimal hepatic encephalopathy -current validation level and practical use[J]. Metab Brain Dis, 2022, 37(3): 589-605. DOI: 10.1007/s11011-022-00913-w.
    [18]
    BAJAJ JS, WADE JB, SANYAL AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy[J]. Hepatology, 2009, 50(6): 2014-2021. DOI: 10.1002/hep.23216.
    [19]
    HADJIHAMBI A, ARIAS N, SHEIKH M, et al. Hepatic encephalopathy: a critical current review[J]. Hepatol Int, 2018, 12(Suppl 1): 135-147. DOI: 10.1007/s12072-017-9812-3.
    [20]
    SORIANO G, BAJAJ JS. Grading the range of hepatic encephalopathy from overt to covert: Animals to the rescue![J]. Hepatology, 2017, 66(1): 10-12. DOI: 10.1002/hep.29186.
    [21]
    ELSAID MI, RUSTGI VK, LOO N, et al. The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease[J]. J Med Econ, 2020, 23(4): 378-385. DOI: 10.1080/13696998.2019.1699563.
    [22]
    TAN L, MENG Y, ZENG T, et al. Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy[J]. Br J Biomed Sci, 2019, 76(1): 24-28. DOI: 10.1080/09674845.2018.1523673.
    [23]
    AMPUERO J, MONTOLIÚ C, SIMÓN-TALERO M, et al. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression[J]. J Gastroenterol Hepatol, 2018, 33(3): 718-725. DOI: 10.1111/jgh.13917.
    [24]
    RIGGIO O, AMODIO P, FARCOMENI A, et al. A model for predicting development of overt hepatic encephalopathy in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2015, 13(7): 1346-1352. DOI: 10.1016/j.cgh.2014.12.025.
    [25]
    MONTAGNESE S, RUSSO FP, AMODIO P, et al. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)[J]. Dig Liver Dis, 2019, 51(2): 190-205. DOI: 10.1016/j.dld.2018.11.035.
    [26]
    GAO YY, ZHANG X, LI FH, et al. Measurement of glycosylated albumin and its application value in liver cirrhosis patients with different Child-Pugh classes[J]. Clin Hepatal, 2022, 38(2): 347-351. DOI: 10.3969/j.issn.1001-5256.2022.02.018.

    高艳颖, 张旭, 李凤慧, 等. 不同child-pugh分级肝硬化患者糖化白蛋白的测定及其应用价值[J]. 临床肝胆病杂志, 2022, 38(2): 347-351. DOI: 10.3969/j.issn.1001-5256.2022.02.018.
    [27]
    DJIAMBOU-NGANJEU H. Hepatic encephalopathy in liver cirrhosis[J]. J Transl Int Med, 2017, 5(1): 64-67. DOI: 10.1515/jtim-2017-0013.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Article Metrics

    Article views (761) PDF downloads(66) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return